$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000106282220000015 Filed on March 12, 2020

Income Statement

Concept	2019 Q4	2019 Q2	2019 Q1
Revenue	$8.727M	$9.682M	$9.216M
YoY Change	-48.88%	-29.83%	-63.68%
Cost Of Revenue	$800.0K	$1.327M	$553.0K
YoY Change	33.33%	58.35%	3.75%
Gross Profit	$8.000M	$8.355M	$8.663M
YoY Change	-52.38%	-35.53%	-65.13%
Gross Profit Margin	91.67%	86.29%	94.0%
Selling, General & Admin	$14.60M	$14.30M	$14.10M
YoY Change	-12.05%	-14.88%	-5.1%
% of Gross Profit	182.5%	171.15%	162.76%
Research & Development	$40.60M	$12.64M	$12.02M
YoY Change	235.54%	-52.27%	-74.79%
% of Gross Profit	507.5%	151.25%	138.77%
Depreciation & Amortization	$1.000M	$900.0K	$901.0K
YoY Change	11.11%	-10.0%	-2.59%
% of Gross Profit	12.5%	10.77%	10.4%
Operating Expenses	$55.10M	$28.23M	$26.69M
YoY Change	92.66%	-35.95%	-57.7%
Operating Profit	-$47.22M	-$18.55M	-$17.47M
YoY Change	281.8%	-38.74%	-53.68%
Interest Expense	-$5.200M	$5.164M	$5.117M
YoY Change	0.0%	-0.44%	0.08%
% of Operating Profit
Other Income/Expense, Net	$1.300M	$691.0K	$789.0K
YoY Change	62.5%	-24.07%	-21.49%
Pretax Income	-$51.10M	-$23.00M	-$21.80M
YoY Change	213.5%	-33.73%	-48.19%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$51.14M	-$23.02M	-$21.80M
YoY Change	204.72%	-33.38%	-47.88%
Net Earnings / Revenue	-585.97%	-237.74%	-236.51%
Basic Earnings Per Share	-$0.48	-$0.22	-$0.21
Diluted Earnings Per Share	-$0.48	-$0.22	-$0.21
COMMON SHARES
Basic Shares Outstanding	106.3M shares	106.3M shares	106.1M shares
Diluted Shares Outstanding	106.3M shares	106.3M shares	106.1M shares

Balance Sheet

Concept	2019 Q4	2019 Q2	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$271.7M	$106.0M	$133.1M
YoY Change	69.71%	-49.45%	-49.26%
Cash & Equivalents	$36.11M	$11.11M	$45.78M
Short-Term Investments	$235.5M	$94.90M	$87.40M
Other Short-Term Assets	$5.320M	$6.625M	$4.686M
YoY Change	99.4%	67.55%	9.38%
Inventory	$4.243M	$4.277M	$4.606M
Prepaid Expenses
Receivables	$56.53M	$5.580M	$4.390M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$337.8M	$122.5M	$146.8M
YoY Change	94.87%	-44.39%	-46.25%
LONG-TERM ASSETS
Property, Plant & Equipment	$14.05M	$15.01M	$15.48M
YoY Change	-11.46%	-10.52%	-10.26%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles	$19.70M	$49.24M	$49.68M
YoY Change	-60.69%	-3.46%	-3.43%
Long-Term Investments
YoY Change
Other Assets	$1.655M	$1.898M	$1.993M
YoY Change	480.7%	342.42%	361.34%
Total Long-Term Assets	$79.96M	$110.7M	$111.7M
YoY Change	-27.84%	-1.83%	-1.74%
TOTAL ASSETS
Total Short-Term Assets	$337.8M	$122.5M	$146.8M
Total Long-Term Assets	$79.96M	$110.7M	$111.7M
Total Assets	$417.7M	$233.1M	$258.5M
YoY Change	47.01%	-29.97%	-33.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$12.18M	$10.03M	$13.87M
YoY Change	1.05%	-80.12%	-79.15%
Accrued Expenses	$42.15M	$9.083M	$10.80M
YoY Change	98.4%	-29.4%	-16.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.01M	$1.115M	$1.115M
YoY Change	887.62%	-91.35%	-91.75%
Total Short-Term Liabilities	$65.34M	$22.47M	$28.22M
YoY Change	77.79%	-72.38%	-71.88%
LONG-TERM LIABILITIES
Long-Term Debt	$234.2M	$244.0M	$243.9M
YoY Change	-3.98%	5.06%	5.19%
Other Long-Term Liabilities	$1.102M	$1.325M	$1.433M
YoY Change	363.03%	400.0%	413.62%
Total Long-Term Liabilities	$235.3M	$245.3M	$245.3M
YoY Change	-3.63%	5.51%	5.68%
TOTAL LIABILITIES
Total Short-Term Liabilities	$65.34M	$22.47M	$28.22M
Total Long-Term Liabilities	$235.3M	$245.3M	$245.3M
Total Liabilities	$300.6M	$298.0M	$304.2M
YoY Change	-3.2%	-11.83%	-15.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.341B	-$1.516B	-$1.493B
YoY Change	-8.84%	5.02%	5.97%
Common Stock	$106.0K	$106.0K	$106.0K
YoY Change	0.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$3.817M	$3.817M	$3.817M
YoY Change	32.72%	32.72%	32.72%
Treasury Stock Shares	407.0K shares	407.0K shares	407.0K shares
Shareholders Equity	$117.1M	-$64.89M	-$45.69M
YoY Change
Total Liabilities & Shareholders Equity	$417.7M	$233.1M	$258.5M
YoY Change	47.01%	-29.97%	-33.17%

Cashflow Statement

Concept	2019 Q4	2019 Q2	2019 Q1
OPERATING ACTIVITIES
Net Income	-$51.14M	-$23.02M	-$21.80M
YoY Change	204.72%	-33.38%	-47.88%
Depreciation, Depletion And Amortization	$1.000M	$900.0K	$901.0K
YoY Change	11.11%	-10.0%	-2.59%
Cash From Operating Activities	-$24.40M	-$26.90M	-$25.62M
YoY Change	-9.96%	-48.76%	-45.23%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$70.00K
YoY Change		-100.0%	75.0%
Acquisitions
YoY Change
Other Investing Activities	-$109.4M	-$7.400M	-$7.700M
YoY Change	-286.05%	-115.61%	-208.45%
Cash From Investing Activities	-$109.4M	-$7.500M	-$7.726M
YoY Change	-286.05%	-115.86%	-209.39%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$941.0K
YoY Change			-0.63%
Debt Paid & Issued, Net			$321.0K
YoY Change			-44.75%
Cash From Financing Activities	-300.0K	-300.0K	-$1.262M
YoY Change	200.0%	50.0%	-17.41%
NET CHANGE
Cash From Operating Activities	-24.40M	-26.90M	-$25.62M
Cash From Investing Activities	-109.4M	-7.500M	-$7.726M
Cash From Financing Activities	-300.0K	-300.0K	-$1.262M
Net Change In Cash	-134.1M	-34.70M	-$34.61M
YoY Change	-524.37%	542.59%	-16.08%
FREE CASH FLOW
Cash From Operating Activities	-$24.40M	-$26.90M	-$25.62M
Capital Expenditures	$0.00	$0.00	$70.00K
Free Cash Flow	-$24.40M	-$26.90M	-$25.69M
YoY Change	-9.96%	-48.66%	-45.12%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2019	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
CY2019	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2019	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
CY2019	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2019	dei	Amendment Flag AmendmentFlag	false
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4000	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	4000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	61741000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	60006000	USD
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	407000	shares
CY2018Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	236000	shares
CY2019	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	7096000	USD
CY2018	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	6010000	USD
CY2017	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	4905000	USD
CY2019	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	7122000	USD
CY2018	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	5686000	USD
CY2017	lxrx	Stock Based Compensation Expense Associated With General And Administrative Expense StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense	4567000	USD
CY2018	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2017	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2018	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2014Q4	us-gaap	Debt Instrument Term DebtInstrumentTerm	P7Y
CY2018Q3	us-gaap	Debt Instrument Term DebtInstrumentTerm	P2Y
CY2018Q3	us-gaap	Debt Instrument Term DebtInstrumentTerm	P2Y
CY2017Q4	us-gaap	Debt Instrument Term DebtInstrumentTerm	P5Y
CY2019	lxrx	Defined Contribution Plan Requisite Service Period DefinedContributionPlanRequisiteServicePeriod	P4Y
CY2015Q4	lxrx	Research And Development Arrangement Contract To Perform For Others Development Costs Period ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod	P3Y
CY2019	dei	Document Type DocumentType	10-K
CY2019	dei	Document Annual Report DocumentAnnualReport	true
CY2019	dei	Document Period End Date DocumentPeriodEndDate	2019-12-31
CY2019	dei	Document Transition Report DocumentTransitionReport	false
CY2019	dei	Entity File Number EntityFileNumber	000-30111
CY2019	dei	Entity Registrant Name EntityRegistrantName	Lexicon Pharmaceuticals, Inc.
CY2019	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2019	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0474169
CY2019	dei	Entity Address Address Line1 EntityAddressAddressLine1	8800 Technology Forest Place
CY2019	dei	City Area Code CityAreaCode	(281)
CY2019	dei	Local Phone Number LocalPhoneNumber	863-3000
CY2019	dei	Entity Address City Or Town EntityAddressCityOrTown	The Woodlands
CY2019	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2019	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77381
CY2019	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2019	dei	Trading Symbol TradingSymbol	LXRX
CY2019	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2019	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2019	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2019	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2019	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2019	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2019	dei	Entity Small Business EntitySmallBusiness	false
CY2019	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2019	dei	Entity Shell Company EntityShellCompany	false
CY2019Q2	dei	Entity Public Float EntityPublicFloat	259500000	USD
CY2020Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	106969973	shares
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36112000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80386000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	235547000	USD
CY2018Q4	us-gaap	Short Term Investments ShortTermInvestments	79666000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	56532000	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	5924000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	4243000	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	4680000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5320000	USD
CY2018Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2668000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	337754000	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	173324000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14047000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15865000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2018Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2019Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	19716000	USD
CY2018Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	50119000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1655000	USD
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	285000	USD
CY2019Q4	us-gaap	Assets Assets	417715000	USD
CY2018Q4	us-gaap	Assets Assets	284136000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12178000	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12052000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	42151000	USD
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21245000	USD
CY2019Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0	USD
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	2339000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	11012000	USD
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	1115000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	65341000	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	36751000	USD
CY2019Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
CY2018Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	23651000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	234171000	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	243887000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	0	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	6014000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1102000	USD
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	238000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	300614000	USD
CY2018Q4	us-gaap	Liabilities Liabilities	310541000	USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	106000	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	106000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1462172000	USD
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1447954000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1341444000	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1471577000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	84000	USD
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-12000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3817000	USD
CY2018Q4	us-gaap	Treasury Stock Value TreasuryStockValue	2876000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	117101000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-26405000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	417715000	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	284136000	USD
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	32331000	USD
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	26583000	USD
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	15890000	USD
CY2019	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	289231000	USD
CY2018	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	36271000	USD
CY2017	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	75621000	USD
CY2019	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	511000	USD
CY2018	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	355000	USD
CY2017	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	178000	USD
CY2019	us-gaap	Revenues Revenues	322073000	USD
CY2018	us-gaap	Revenues Revenues	63209000	USD
CY2017	us-gaap	Revenues Revenues	91689000	USD
CY2019	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3231000	USD
CY2018	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2491000	USD
CY2017	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1899000	USD
CY2019	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	91924000	USD
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	100243000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	152223000	USD
CY2019	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	0	USD
CY2018	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	0	USD
CY2017	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	2101000	USD
CY2019	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	56835000	USD
CY2018	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	63754000	USD
CY2017	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	66090000	USD
CY2019	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	28638000	USD
CY2018	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	USD
CY2019	us-gaap	Operating Expenses OperatingExpenses	180628000	USD
CY2018	us-gaap	Operating Expenses OperatingExpenses	166488000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	222313000	USD
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	141445000	USD
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	-103279000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-130624000	USD
CY2019	us-gaap	Interest Expense InterestExpense	20676000	USD
CY2018	us-gaap	Interest Expense InterestExpense	20777000	USD
CY2017	us-gaap	Interest Expense InterestExpense	6984000	USD
CY2019	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3350000	USD
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	3508000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1954000	USD
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	124119000	USD
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-120548000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-135654000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6014000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-12661000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	130133000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-120548000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-122993000	USD
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	732000	USD
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.23
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.17
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.16
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.14
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.17
CY2019	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	106218000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	105830000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	105237000	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116747000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105830000	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105237000	shares
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	96000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-27000	USD
CY2019	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	130229000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	210000	USD
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-120338000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-123020000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	167507000	USD
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9472000	USD
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	5486000	USD
CY2017	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	1679000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-122993000	USD
CY2017	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-27000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	68265000	USD
CY2018	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification	14212000	USD
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11696000	USD
CY2018	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	972000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-120548000	USD
CY2018	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	210000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	-26405000	USD
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14218000	USD
CY2019	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	0	USD
CY2019	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	941000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	130133000	USD
CY2019	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	96000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	117101000	USD
CY2019	us-gaap	Profit Loss ProfitLoss	130133000	USD
CY2018	us-gaap	Profit Loss ProfitLoss	-120548000	USD
CY2017	us-gaap	Profit Loss ProfitLoss	-122993000	USD
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3654000	USD
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3683000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	3399000	USD
CY2019	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	0	USD
CY2018	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	0	USD
CY2017	lxrx	Change In Fair Value Of Symphony Icon Inc Purchase Liability ChangeInFairValueOfSymphonyIconIncPurchaseLiability	2101000	USD
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	14218000	USD
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	11696000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	9472000	USD
CY2019	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2018	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	0	USD
CY2017	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	-3000	USD
CY2019	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1465000	USD
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1336000	USD
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	599000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6014000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-12661000	USD
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	50608000	USD
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1099000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-166000	USD
CY2019	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-437000	USD
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2732000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1948000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1948000	USD
CY2019	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2652000	USD
CY2018	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1766000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	557000	USD
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-429000	USD
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-144000	USD
CY2017	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-33000	USD
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	20097000	USD
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-19913000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-11875000	USD
CY2019	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-25990000	USD
CY2018	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-22940000	USD
CY2017	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-51133000	USD
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	113807000	USD
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-148607000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-185394000	USD
CY2019	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70000	USD
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	95000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	228000	USD
CY2019	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	322385000	USD
CY2018	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	119987000	USD
CY2017	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	267873000	USD
CY2019	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	166600000	USD
CY2018	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	289658000	USD
CY2017	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	318623000	USD
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-155855000	USD
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	169576000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	50522000	USD
CY2019	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	732000	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	7987000	USD
CY2019	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	941000	USD
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	972000	USD
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1679000	USD
CY2019	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	12529000	USD
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	145905000	USD
CY2019	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1285000	USD
CY2018	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	14533000	USD
CY2017	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2280000	USD
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2226000	USD
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2244000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	149933000	USD
CY2019	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-44274000	USD
CY2018	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	18725000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	15061000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80386000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61661000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	46600000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36112000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80386000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61661000	USD
CY2019	us-gaap	Interest Paid Net InterestPaidNet	19211000	USD
CY2018	us-gaap	Interest Paid Net InterestPaidNet	16465000	USD
CY2017	us-gaap	Interest Paid Net InterestPaidNet	5870000	USD
CY2019	lxrx	Shares Issued To Symphony Designees Value SharesIssuedToSymphonyDesigneesValue	0	USD
CY2018	lxrx	Symphony Contingent Payment In Cash SymphonyContingentPaymentInCash	0	USD
CY2017	lxrx	Shares Issued To Symphony Designees Value SharesIssuedToSymphonyDesigneesValue	10499000	USD
CY2018Q4	lxrx	Prior Year Reclass Of Accrual PriorYearReclassOfAccrual	5700000	USD
CY2019	us-gaap	Use Of Estimates UseOfEstimates	<span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">Use of Estimates:</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (“GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span>
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3182000	USD
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3564000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	153000	USD
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	232000	USD
CY2018Q4	us-gaap	Inventory Gross InventoryGross	4680000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	908000	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	884000	USD
CY2019Q4	us-gaap	Inventory Gross InventoryGross	4243000	USD
CY2019	lxrx	Disclosure On Geographic Areas Revenue From External Customers Attributed To Germany DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany	0.89
CY2019	lxrx	Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent	0.10
CY2018	lxrx	Disclosure On Geographic Areas Revenue From External Customers Attributed To Germany DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany	0.53
CY2018	lxrx	Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent	0.40
CY2017	lxrx	Disclosure On Geographic Areas Revenue From External Customers Attributed To Germany DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToGermany	0.65
CY2017	lxrx	Disclosure On Geographic Areas Revenue From External Customers Attributedto France DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance	0.18
CY2017	lxrx	Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent	0.17
CY2019	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2019	lxrx	Entity Wide Revenue Sanofi Percentage EntityWideRevenueSanofiPercentage	0.89
CY2018	lxrx	Entity Wide Revenue Sanofi Percentage EntityWideRevenueSanofiPercentage	0.53
CY2018	lxrx	Lxrx Biologicscustomerconcentration LXRXBiologicscustomerconcentration	0.25
CY2018	lxrx	Lxrx Diplomatcustomerconcentration LXRXDiplomatcustomerconcentration	0.14
CY2017	lxrx	Entity Wide Revenue Sanofi Percentage EntityWideRevenueSanofiPercentage	0.65
CY2017	lxrx	Entity Wide Revenue Ipsen Percentage EntityWideRevenueIpsenPercentage	0.18
	lxrx	Xermelo Intangible Assets Finite Lived XERMELOIntangibleAssetsFiniteLived	24700000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1766000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1766000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1766000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1766000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1766000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	10886000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	19716000	USD
CY2019	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	28600000	USD
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2019	lxrx	Cost Of Goods And Services Sold Period Reflecting Lower Average Per Unit Cost Of Materials CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials	P12M
CY2019Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	24000000.0	USD
CY2019	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y1M6D
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	333600000	USD
CY2019Q4	lxrx	Deferred Tax Assets Tax Credit Carryforwards Orphan Drug DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug	24524000	USD
CY2019	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	36112000	USD
CY2019Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	235547000	USD
CY2019Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	271659000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	80386000	USD
CY2018Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	79666000	USD
CY2018Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	160052000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	75788000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	75871000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	61741000	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	60006000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14047000	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	15865000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	193270000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	206789000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	46306000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	47087000	USD
CY2018Q4	lxrx	Deferred Tax Assets Tax Credit Carryforwards Orphan Drug DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug	24524000	USD
CY2019Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	58596000	USD
CY2018Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	71047000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5340000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4641000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	0	USD
CY2018Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	5458000	USD
CY2018Q4	lxrx	Deferred Tax Assets Section163j Lxrx DeferredTaxAssetsSection163j_LXRX	3625000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	5533000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	6044000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	333569000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	369215000	USD
CY2019Q4	lxrx	Deferred Tax Liability Related To Acquisition Of Symphony Icon DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon	4140000	USD
CY2018Q4	lxrx	Deferred Tax Liability Related To Acquisition Of Symphony Icon DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon	10525000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	3000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2000	USD
CY2018Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6014000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4143000	USD
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	10527000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	329426000	USD
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	364702000	USD
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2019Q4	lxrx	Deferred Tax Liability Related To Acquisition Of Symphony Icon DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon	4100000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.21
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.21
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.35
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	26065000	USD
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-25315000	USD
CY2017	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-47479000	USD
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	445000	USD
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-809000	USD
CY2017	lxrx	Effective Income Tax Rate Reconciliation Symphony Icon Fv Adjustment EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment	735000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-2324000	USD
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	1688000	USD
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	1059000	USD
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Amount EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount	1447000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	0	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	-978000	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	-1993000	USD
CY2019	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0	USD
CY2018	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	0	USD
CY2017	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	-189000	USD
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	0	USD
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	0	USD
CY2017	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-5316000	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	0	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	169464000	USD
CY2018	lxrx	Effective Income Tax Rate Reconciliation Symphony Icon Fv Adjustment EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment	0	USD
CY2019	lxrx	Effective Income Tax Rate Reconciliation Symphony Icon Fv Adjustment EffectiveIncomeTaxRateReconciliationSymphonyIconFVAdjustment	0	USD
CY2019	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-35276000	USD
CY2018	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	25928000	USD
CY2017	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-126634000	USD
CY2019	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	1064000	USD
CY2018	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	115000	USD
CY2017	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-372000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6014000	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-12661000	USD
CY2019Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	879700000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards State And Local DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal	83000000.0	USD
CY2019	lxrx	Federal Net Operating Loss Change FederalNetOperatingLossChange	62200000	USD
CY2019Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	46300000	USD
CY2019	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	35300000	USD
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6000000.0	USD
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-12700000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-12700000	USD
CY2017Q1	lxrx	Deferred Tax Liabilityfrom Reclassified Intangible Asset DeferredTaxLiabilityfromReclassifiedIntangibleAsset	8700000	USD
CY2017Q4	lxrx	Deferred Tax Liabilityfrom Reclassified Indefinitelived Intangible DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible	4000000.0	USD
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2001Q3	lxrx	Coelacanth Goodwill CoelacanthGoodwill	25800000	USD
CY2001Q3	lxrx	Coelacanth Purchase Price CoelacanthPurchasePrice	36000000.0	USD
CY2010Q3	lxrx	Symphony Icon Goodwill SymphonyIconGoodwill	18700000	USD
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	USD
CY2019Q4	lxrx	Convertible Debt Instrument Interest Rate Stated Percentage ConvertibleDebtInstrumentInterestRateStatedPercentage	0.0525
CY2019Q4	lxrx	Convertible Debt Instrument Interest Rate Stated Percentage ConvertibleDebtInstrumentInterestRateStatedPercentage	0.0525
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	118.4553
CY2019Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.442
CY2019	lxrx	Debt Instrument Repurchase Percentage DebtInstrumentRepurchasePercentage	1
CY2014Q4	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3400000	USD
CY2019Q4	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	900000	USD
CY2019Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	64800000	USD
CY2018Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2018Q3	lxrx	Mortgage Debt Instrument Revere Lxrx MortgageDebtInstrument_Revere_LXRX	12900000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P10Y
CY2018Q3	lxrx	Mortgage Debt Interest Rate Base Revere Lxrx MortgageDebtInterestRate_Base_Revere_LXRX	0.055
CY2018Q3	lxrx	Mortgage Debt Interest Rate Base Plus Revere Lxrx MortgageDebtInterestRateBasePlus_Revere_LXRX	0.075
CY2018Q3	lxrx	Mortgage Debt Balloon Payment Lxrx MortgageDebtBalloonPayment_LXRX	10300000	USD
CY2018Q3	lxrx	Mortgage Debt Issue Costs Revere Lxrx MortgageDebtIssueCosts_Revere_LXRX	400000	USD
CY2019Q4	lxrx	Mortgage Debt Issue Costs Revere Lxrx MortgageDebtIssueCosts_Revere_LXRX	100000	USD
CY2019Q4	us-gaap	Mortgage Loans On Real Estate MortgageLoansOnRealEstate	11000000.0	USD
CY2019Q4	lxrx	Buildings Collateral BuildingsCollateral	59200000	USD
CY2019Q4	lxrx	Land Collateral LandCollateral	2700000	USD
CY2017Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000000	USD
CY2019Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.09
CY2017Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	4100000	USD
CY2019Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	2400000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	11130000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	87500000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	150000000	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	0	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2019Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal After Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive	0	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	248630000	USD
CY2019Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	3447000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	11012000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	234171000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1700000	USD
CY2019Q4	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	-600000	USD
CY2019Q4	lxrx	Total Shares That May Be Issued Equity Incentive Plan TotalSharesThatMayBeIssuedEquityIncentivePlan	20000000	shares
CY2019	lxrx	Stock Option Exercise Price As Percent Of Value Of Common Stock StockOptionExercisePriceAsPercentOfValueOfCommonStock	1
CY2019Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1100000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	620000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	632000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	645000	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	0	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	0	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	0	USD
CY2019Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	1897000	USD
CY2019	lxrx	Interest On Lease Payments InterestOnLeasePayments	-242000	USD
CY2019Q4	lxrx	Present Value Of Future Lease Payments PresentValueOfFutureLeasePayments	1655000	USD
CY2019Q4	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	-553000	USD
CY2019Q4	us-gaap	Long Term Debt And Capital Lease Obligations LongTermDebtAndCapitalLeaseObligations	1102000	USD
CY2019Q4	lxrx	Options Outstanding Equity Incentive Plan OptionsOutstandingEquityIncentivePlan	7456905	shares
CY2019Q4	lxrx	Restricted Stock Units Outstanding Equity Incentive Plan RestrictedStockUnitsOutstandingEquityIncentivePlan	2801928	shares
CY2019Q4	lxrx	Stock Options Exercised Equity Incentive Plan StockOptionsExercisedEquityIncentivePlan	1909515	shares
CY2019Q4	lxrx	Shares Issued Pursuant To Restricted Stock Units Equity Incentive Plan SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan	1968979	shares
CY2019Q4	lxrx	Shares Issued Pursuant To Stock Bonus Awards Equity Incentive Plan SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan	113940	shares
CY2019Q4	lxrx	Totalvalueofsharesbynonemployeeinayear Totalvalueofsharesbynonemployeeinayear	500000	USD
CY2019Q4	lxrx	Total Shares That May Be Issued Non Employee Directors Equity Incentive Plan TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan	600000	shares
CY2019Q4	lxrx	Options Outstanding Non Employee Directors Equity Incentive Plan OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan	237850	shares
CY2019Q4	lxrx	Stock Options Exercised Non Employee Directors Equity Incentive Plan StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan	0	shares
CY2019Q4	lxrx	Shares Issued Pursuant To Restricted Stock Awards Non Employee Directors Equity Incentive Plan SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan	103208	shares
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.18
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.63
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.59
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2000000.0	USD
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M18D
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y3M18D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	200000	USD
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	USD
CY2019	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod	27728	shares
CY2018	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod	20512	shares
CY2017	lxrx	Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod	10248	shares
CY2019	lxrx	Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue	5.67
CY2018	lxrx	Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue	7.80
CY2017	lxrx	Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue	15.61
CY2019	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	2900000	USD
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	3300000	USD
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Total Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue	4700000	USD
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	10524411	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	5979947	shares
CY2019	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1200000	USD
CY2018	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1000000.0	USD
CY2017	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	1000000.0	USD
CY2019	lxrx	Settlement Payment From Termination SettlementPaymentFromTermination	208000000	USD
CY2019Q4	lxrx	Settlement Payment Obligation SettlementPaymentObligation	26000000	USD
CY2015Q4	lxrx	Sanofi Upfront Payment SanofiUpfrontPayment	300000000	USD
CY2015Q4	lxrx	Sanofi Development Milestones SanofiDevelopmentMilestones	110000000	USD
CY2015Q4	lxrx	Research And Development Arrangement Contract To Perform For Others Number Of Development Milestones ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones	4	milestone
CY2015Q4	lxrx	Sanofi Regulatory Milestones SanofiRegulatoryMilestones	220000000	USD
CY2015Q4	lxrx	Research And Development Arrangement Contract To Perform For Others Number Of Regulatory Milestones ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones	4	milestone
CY2015Q4	lxrx	Sanofi Outcomes Study Milestone SanofiOutcomesStudyMilestone	100000000	USD
CY2015Q4	lxrx	Sanofi Sales Milestone Payments SanofiSalesMilestonePayments	990000000	USD
CY2015Q4	lxrx	Research And Development Arrangement Contract To Perform For Others Number Of Commercial Milestones ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones	6	milestone
CY2015Q4	lxrx	Research And Development Arrangement Contract To Perform For Others Royalties Percentage ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage	0.40
CY2015Q4	lxrx	Research And Development Arrangement Contract To Perform For Others Commercial Costs Funded Percentage ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage	0.40
CY2015Q4	lxrx	Sanofi Commercialization Costs Fundedby Lexicon Maximum Amount SanofiCommercializationCostsFundedbyLexiconMaximumAmount	100000000	USD
CY2015Q4	lxrx	Research And Development Arrangement Contract To Perform For Others Expiration Period ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod	P10Y
CY2015Q4	lxrx	Sanofi Upfront Payment SanofiUpfrontPayment	300000000	USD
CY2015Q4	lxrx	Sanofi Upfront Payment SanofiUpfrontPayment	300000000	USD
CY2015Q4	lxrx	Sanofi Commercialization Costs Fundedby Lexicon Maximum Amount SanofiCommercializationCostsFundedbyLexiconMaximumAmount	100000000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto License Deliverable SanofiRevenueAllocatedtoLicenseDeliverable	126800000	USD
CY2015Q4	lxrx	Sanofi Upfront Payment SanofiUpfrontPayment	300000000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto Development Deliverable SanofiRevenueAllocatedtoDevelopmentDeliverable	113800000	USD
CY2015Q4	lxrx	Sanofi Revenue Allocatedto Funding Deliverable SanofiRevenueAllocatedtoFundingDeliverable	59400000	USD
CY2019	lxrx	Sanofi Deferred Revenue From Termination SanofiDeferredRevenueFromTermination	23500000	USD
CY2019	lxrx	Sanofi Termination Agreement SanofiTerminationAgreement	260000000	USD
CY2019	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	286000000	USD
CY2018	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	33200000	USD
CY2017	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	60100000	USD
CY2019Q4	lxrx	Ipsen Total Payments To Date IpsenTotalPaymentsToDate	47200000	USD
CY2014Q4	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2016Q3	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	6400000	USD
CY2019Q3	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	5100000	USD
CY2017Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	3800000	USD
CY2017Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	3800000	USD
CY2018Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	1300000	USD
CY2014Q4	lxrx	Ipsen Maximum Regulatory And Commercial Milestones IpsenMaximumRegulatoryAndCommercialMilestones	9600000	USD
CY2014Q4	lxrx	Ipsen Maximum Sales Milestones IpsenMaximumSalesMilestones	72000000	EUR
CY2014Q4	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2014Q4	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	21200000	USD
CY2014Q4	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2018	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	1400000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Development Deliverable IpsenRevenueAllocatedtoDevelopmentDeliverable	1700000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Committee Deliverable IpsenRevenueAllocatedtoCommitteeDeliverable	100000	USD
CY2019	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	4900000	USD
CY2018	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	4600000	USD
CY2017	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	16200000	USD
CY2019	lxrx	Ipsen Royalty Income Lxrx IpsenRoyaltyIncome_LXRX	300000	USD
CY2018	lxrx	Ipsen Royalty Income Lxrx IpsenRoyaltyIncome_LXRX	100000	USD
CY2019	lxrx	Ipsenproductsales Ipsenproductsales	1600000	USD
CY2018	lxrx	Ipsenproductsales Ipsenproductsales	800000	USD
CY2019	us-gaap	Net Income Loss NetIncomeLoss	130133000	USD
CY2018	us-gaap	Net Income Loss NetIncomeLoss	-120548000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-122993000	USD
CY2019	us-gaap	Debt Instrument Convertible If Converted Value In Excess Of Principal DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal	5067000	USD
CY2018	us-gaap	Debt Instrument Convertible If Converted Value In Excess Of Principal DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal	0	USD
CY2017	us-gaap	Debt Instrument Convertible If Converted Value In Excess Of Principal DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal	0	USD
CY2019	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	135200000	USD
CY2018	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-120548000	USD
CY2017	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	-122993000	USD
CY2019	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	106218000	shares
CY2018	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	105830000	shares
CY2017	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	105237000	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	164000	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2019	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	10365000	shares
CY2018	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2019	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116747000	shares
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105830000	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	105237000	shares
CY2019	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.23
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.17
CY2019	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.16
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.14
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.17
CY2019	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8206390	shares
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7438134	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5907643	shares
CY2019Q1	us-gaap	Revenues Revenues	9216000	USD
CY2019Q2	us-gaap	Revenues Revenues	9682000	USD
CY2019Q3	us-gaap	Revenues Revenues	294448000	USD
CY2019Q4	us-gaap	Revenues Revenues	8727000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-17469000	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-18545000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	224676000	USD
CY2019Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-47217000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-21797000	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-23018000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	226086000	USD
CY2019Q4	us-gaap	Net Income Loss NetIncomeLoss	-51138000	USD
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.21
CY2019Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.22
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.13
CY2019Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.48
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.21
CY2019Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.22
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.95
CY2019Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.48
CY2019Q1	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	106054000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	106272000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	106272000	shares
CY2019Q4	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	106272000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106054000	shares
CY2019Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106272000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116640000	shares
CY2019Q4	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106272000	shares
CY2018Q1	us-gaap	Revenues Revenues	25374000	USD
CY2018Q2	us-gaap	Revenues Revenues	13798000	USD
CY2018Q3	us-gaap	Revenues Revenues	6966000	USD
CY2018Q4	us-gaap	Revenues Revenues	17071000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-37713000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-30272000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-22927000	USD
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-12367000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-41821000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-34549000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-27396000	USD
CY2018Q4	us-gaap	Net Income Loss NetIncomeLoss	-16782000	USD
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.40
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.26
CY2018Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105668000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105848000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105881000	shares
CY2018Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	105920000	shares
CY2019	lxrx	Sanofi Termination Agreement SanofiTerminationAgreement	260000000	USD

Files In Submission

Name	View Source	Status
0001062822-20-000015-index-headers.html	Edgar Link	pending
0001062822-20-000015-index.html	Edgar Link	pending
0001062822-20-000015.txt	Edgar Link	pending
0001062822-20-000015-xbrl.zip	Edgar Link	pending
exh1011officerrestrict.htm	Edgar Link	pending
exh1019amendmentno2toi.htm	Edgar Link	pending
exh1082017equityincent.htm	Edgar Link	pending
exh231ernstyoungconsent.htm	Edgar Link	pending
exh311certificationofp.htm	Edgar Link	pending
exh312certificationofp.htm	Edgar Link	pending
exh321certificationofp.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lxrx-20191231.htm	Edgar Link	pending
lxrx-20191231.xsd	Edgar Link	pending
lxrx-20191231_cal.xml	Edgar Link	unprocessable
lxrx-20191231_def.xml	Edgar Link	unprocessable
lxrx-20191231_g1.jpg	Edgar Link	pending
lxrx-20191231_htm.xml	Edgar Link	completed
lxrx-20191231_lab.xml	Edgar Link	unprocessable
lxrx-20191231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2019 Q4 Form 10-K Financial Statement

#000106282220000015 Filed on March 12, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2019 Q4 Form 10-K Financial Statement

#000106282220000015 Filed on March 12, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx